Movement disorders News and Research RSS Feed - Movement disorders News and Research

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015. [More]
Saliva gland test may help diagnose early Parkinson's disease

Saliva gland test may help diagnose early Parkinson's disease

Researchers from Mayo Clinic in Arizona and Banner Sun Health Research Institute have determined that testing a portion of a person's submandibular gland may be a way to diagnose early Parkinson's disease. The study was published this month in Movement Disorders, the official journal of the International Parkinson and Movement Disorders Society. [More]
Researchers reveal link between intensive instrument playing and movement disorders

Researchers reveal link between intensive instrument playing and movement disorders

A musician takes up his/her violin and starts to play, but rather than gripping the strings, the fingers seize up—and this happens every time he/she takes up the instrument. Such a movement disorder—the so-called focal dystonia— is a dramatic disease for those affected, which has thus far barely been studied. [More]
Identifying and avoiding wasteful or unnecessary medical tests

Identifying and avoiding wasteful or unnecessary medical tests

Too many tests at the doctor's office could cost you more than just dollars. In addition to the huge hit to your wallet, there's also the potential harm of false positives, and just because a test has traditionally been done for a condition doesn't mean it's the best way to treat it. [More]
New tool may help diagnose and treat Parkinson's disease in early stages

New tool may help diagnose and treat Parkinson's disease in early stages

A group of experts working under the umbrella of the International Parkinson and Movement Disorder Society, have developed a new tool for healthcare professionals that they hope will mark a significant advancement in the diagnosis and treatment of Parkinson's disease, especially in its early stages. [More]
L-DOPA drug may delay or prevent age-related macular degeneration

L-DOPA drug may delay or prevent age-related macular degeneration

A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD). [More]
Study reveals gene mutation that increases risk of SUDEP in patients with mild forms of disease

Study reveals gene mutation that increases risk of SUDEP in patients with mild forms of disease

Researchers in the Adult Genetic Epilepsy Program of the Krembil Neuroscience Centre have discovered a gene mutation that increases the risk of sudden unexpected death in epilepsy (SUDEP) in patients with mild forms of the disease. [More]
Brain areas linked to social behaviors underdeveloped in youths with high functioning ASD

Brain areas linked to social behaviors underdeveloped in youths with high functioning ASD

A team of UCLA scientists has found that brain areas linked to social behaviors are both underdeveloped and insufficiently networked in youths with high functioning autism spectrum disorder (ASD) compared to study participants without ASD. [More]
Gene therapy prevents neuronal death, disease effects in experimental model of PD

Gene therapy prevents neuronal death, disease effects in experimental model of PD

An estimated seven to ten million people worldwide are living with Parkinson's disease (PD), which is an incurable and progressive disease of the nervous system affecting movement and cognitive function. More than half of PD patients develop progressive disease showing signs of dementia similar to Alzheimer's disease. [More]
Minor hallucinations may predate Parkinson motor symptoms

Minor hallucinations may predate Parkinson motor symptoms

About four in 10 patients with untreated Parkinson’s disease experience minor hallucinations, research shows. [More]
Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder. [More]
Researchers reveal molecular mechanism that controls remyelination

Researchers reveal molecular mechanism that controls remyelination

Researchers in Japan have revealed the molecular mechanism involved in the process of repair to damage of the myelin sheath. In vertebrates, axons extending from nerve cells are covered by insulating sheets called the myelin sheath, made with the cell membranes of oligodendrocytes, enabling fast electrical signaling through saltatory conduction. [More]
Cognitive impairment may be part of prodromal PD

Cognitive impairment may be part of prodromal PD

Research shows that people with a theoretical high risk of developing Parkinson’s disease (PD) have significant cognitive deficits, particularly affecting executive function. [More]
University of Maryland Medicine offers MRI-guided focused ultrasound treatment to Parkinson's patients

University of Maryland Medicine offers MRI-guided focused ultrasound treatment to Parkinson's patients

University of Maryland Medicine (the University of Maryland Medical Center and the University of Maryland School of Medicine) and its Center for Metabolic Imaging and Image-Guided Therapeutics (CMIT) has begun to use MRI-guided focused ultrasound on a deep structure within the brain related to Parkinson's disease - the globus pallidus. [More]
Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Researchers at the University of Maryland and the University of Virginia have performed the first focused ultrasound treatments in the United States for dyskinesia associated with Parkinson's disease. [More]
September tip sheet from Cedars-Sinai Medical Center

September tip sheet from Cedars-Sinai Medical Center

A computer algorithm did a better job than doctors at documenting "red flag" symptoms among patients with gastrointestinal disorders, a Cedars-Sinai study has found, underscoring the potential of the technology to improve patient care. [More]
Robert Wood Johnson Medical Group physicians selected for Best Doctors in America List for 2015-2016

Robert Wood Johnson Medical Group physicians selected for Best Doctors in America List for 2015-2016

Sixty-one physicians affiliated with Robert Wood Johnson Medical Group, the faculty practice of Rutgers Robert Wood Johnson Medical School, were selected for the Best Doctors in America® List for 2015-2016. Only 5 percent of physicians in the United States earn this prestigious honor, determined by impartial peer review. [More]
Newly developed technique delivers wireless power for optogenetics

Newly developed technique delivers wireless power for optogenetics

A miniature device that combines optogenetics - using light to control the activity of the brain - with a newly developed technique for wirelessly powering implanted devices is the first fully internal method of delivering optogenetics. [More]
Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients. [More]
Early cognitive changes linked to white matter damage in Parkinson’s

Early cognitive changes linked to white matter damage in Parkinson’s

Subtle changes in white matter integrity are detectable in patients with Parkinson’s disease and are associated with early impairments in cognition, say researchers. [More]
Advertisement
Advertisement